Q4 FY2023 · ended Dec 31, 2023 · Revenue $10,007, -78.3% YoY · Filed Apr 16, 2024
NP Life Sciences Health Industry Group Inc. (ACAT) files with the SEC under industry code 8200, Services-Educational Services. In Q4 of fiscal 2023, the quarter ended Dec 31, 2023, it reported revenue of $10,007 and a net loss of $15,355.
Revenue
$10,007
-78.3% vs year-ago quarter
Net income
$-15,355
-192.5% vs year-ago quarter
Operating cash flow
$-13,937
-112.1% vs year-ago quarter
Free cash flow
—
EPS
$-0.00
+59.2% vs prior quarter
Dividend per share
None
Shares outstanding
42.96M
+0.0% vs year-ago quarter
Net cash
—
Operating margin
-358.4%
Q4 FY2023
Company profile
- Industry
- Services-Educational Services (SIC 8200)
- Listed as
- ACAT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Danville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1781726
- Former names
- GJ Culture Group US, Inc. (until Sep 29, 2022)
Other Services-Educational Services companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q4 FY2023 Dec 31, 2023 |
Q3 FY2023 Sep 30, 2023 |
Q2 FY2023 Jun 30, 2023 |
Q1 FY2023 Mar 31, 2023 |
Q4 FY2022 Dec 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $10,007 | $17,515 | $107,099 | $30,000 | $46,020 |
| Operating income | -$35,862 | -$37,445 | $71,392 | $1,225 | $16,600 |
| Net income | -$15,355 | -$37,670 | $71,195 | $1,222 | $16,598 |
| Diluted EPS | -$0.00 | -$0.00 | $0.00 | — | — |
| Operating cash flow | -$13,937 | -$40,560 | -$37,329 | $18,219 | $114,908 |
| Total assets | $76,864 | $95,321 | $144,106 | $142,448 | $127,784 |
| Total liabilities | $60,483 | $63,585 | $76,995 | $121,910 | $108,468 |
| Stockholders' equity | $16,381 | — | — | — | — |
| Cash and investments | $70,614 | $84,551 | $125,111 | $140,078 | $121,859 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-K | Annual report | Apr 16, 2024 | Dec 31, 2023 |
| 10-Q | Quarterly report | Nov 14, 2023 | Sep 30, 2023 |
| 10-Q | Quarterly report | Aug 14, 2023 | Jun 30, 2023 |
| 10-Q | Quarterly report | May 15, 2023 | Mar 31, 2023 |
| 10-K | Annual report | Apr 18, 2023 | Dec 31, 2022 |
| 10-Q | Quarterly report | Nov 14, 2022 | Sep 30, 2022 |
All 59 NP Life Sciences Health Industry Group Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.